Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Ev

-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include...

Related Keywords

United States , Jennifer Zibuda , Janet Graesser , Jim Wassil , Groupa Strep , Nasdaq , Drug Administration , Company Expects To Announce Topline Data , Advisory Committee On Immunization Practices , Corporate Communications , Exchange Commission , Sutro Biopharma Inc , Vaxcyte Inc , Study Will Include Prevnar , Announce Topline Data , Primary Immunization Series , Topline Data , Booster Dose Approximately Nine Months , Data Safety Monitoring Board , Grant Pickering , Chief Executive Officer , Advisory Committee , Immunization Practices , Executive Vice President , Chief Operating , Sutro Biopharma , Private Securities Litigation Reform Act , Quarterly Report , Vice President , Senior Director , Investor Relations , Markets ,